Hong Kong Journal of Nephrology
Volume 11, Issue 1 , Pages 20-29 , April 2009

Interactive Joint Scientific Workshop—Treatment Options for Immunosuppression in Different Clinical Scenarios

REFERENCES 

  1. Ekberg H , Tedesco-Silva H , Demirbas A . Reduced exposure to calcineurin inhibitors in renal transplantation . N Engl J Med . 2007;357:2562–2575
  2. Hariharan S , Johnson CP , Bresnahan BA , Taranto SE , McIntosh MJ , Stablein D . Improved graft survival after renal transplantation in the United States, 1988 to 1996 . N Engl J Med . 2000;342:605–612
  3. McDonald S , Russ G , Campbell S , Chadban S . Kidney transplant rejection in Australia and New Zealand: relationship between rejection and graft outcome . Am J Transplant . 2007;7:1201–1208
  4. Briganti EM , Russ GR , McNeil JJ , Atkins RC , Chadban SJ . Risk of renal allograft loss from recurrent glomerulonephritis . N Engl J Med . 2002;347:103–109
  5. Nankivell BJ , Borrows RJ , Fung CLS , O'Connell PJ , Allen RDM , Chapman JRN . The natural history of chronic allograft nephropathy . N Engl J Med . 2003;349:2326–2333
  6. Matas AJ , Humar A , Gillingham KJ , Payne WD , Gruessner RW , Kandaswamy R , et al.   Five preventable causes of kidney graft loss in the 1990s: a single-center analysis . Kidney Int . 2002;62:704–714
  7. Kasiske BL , Chakkera HA , Roel J . Explained and unexplained ischemic heart disease risk after renal transplantation . Am J Soc Nephrol . 2000;11:1735–1743
  8. Cole EH , Johnston O , Rose CL , Gill JS . Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival . Clin J Am Soc Nephrol . 2008;3:814–821
  9. Hjelmesaeth J , Hartmann A , Leivestad T , Holdaas H , Sagedal S , Olstad M , et al.   The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events . Kidney Int . 2006;69:588–595
  10. Johnston O , Rose CL , Webster AC , Gill JS . Sirolimus is associated with new-onset diabetes in kidney transplant recipients . J Am Soc Nephrol . 2008;19:1411–1418
  11. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al  Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus . Am J Transplant . 2007;7:1506–1514 Erratum in: Am J Transplant 2008;8:908; dosage error in text: Am J Transplant 2008;8:1.
  12. Redmon JB , Olson LK , Armstrong MB , Greene MJ , Robertson RP . Effects of tacrolimus (FK506) on human gene expression, insulin mRNA levels and insulin secretion in HIT-T15 cells . JCI . 1996;98:2786–2793
  13. Drachenberg CB , Klassen DK , Weir MR , Wiland A , Fink JC , Bartlett ST , et al.   Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation . Transplant . 1999;68:396–402
  14. Stoeltzing O , Meric-Bernstam F , Ellis LM . Intracellular signaling in tumor and endothelial cells: the expected and, yet again, the unexpected . Cancer Cell . 2006;10:89–91
  15. Huber S , Bruns CJ , Schmid G , Hermann PC , Conrad C , Niess H , et al.   Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis . Kidney Int . 2007;71:771–777

 The opinions expressed in this workshop are those of the speakers and do not represent the official views of the Hong Kong Society of Nephrology, the Hong Kong Society of Transplantation or Elsevier.

PII: S1561-5413(09)60005-3

doi: 10.1016/S1561-5413(09)60005-3

Hong Kong Journal of Nephrology
Volume 11, Issue 1 , Pages 20-29 , April 2009

Article Tools